AMRN Q3 2024 Earnings — Amarin Corporation plc Revenue & Financial Results | Market Cap Arena

AMRNAmarin Corporation plc

$310M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M-36.0% YoY

Gross Profit

$16M38.5% margin

Operating Income

-$25M-59.5% margin

Net Income

-$25M-59.4% margin

EPS (Diluted)

$-1.22

QoQ Revenue Growth

-37.4%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$751M

Total Liabilities

$219M

Stockholders' Equity

$531M

Cash & Equivalents

$157M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$66M	-36.0%
Gross Profit	$16M	$30M	-45.4%
Operating Income	-$25M	-$21M	-17.3%
Net Income	-$25M	-$19M	-30.2%

Revenue Segments

Product

$42M99%

Licensing And Royalty

$446,0001%